BioAtla, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| BioAtla, Inc. | BCAB - NASDAQ |
$15.00-$17.00 | $18.00 | $30.55 | 10.5 million | 12/16/2020 |
| J.P. Morgan, Jefferies, Credit Suisse | ||||||
Co-Manager(s): BTIG | ||||||
| Health Care | ||||||
Filing(s): Terms Added 2020-12-09 Filed 2020-11-13 | ||||||
BioAtla, Inc. Quote & Chart - Click for current quote - BCAB
IPO Boutique aggregates information on public companies and private companies, such as "BCAB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About BioAtla, Inc. (adapted from BioAtla, Inc. prospectus):
They are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "BCAB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.